Eos Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-12-2024
- Paid Up Capital ₹ 0.50 M
as on 09-12-2024
- Company Age 16 Year,
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 8.42 M
as on 09-12-2024
- Revenue -34.99%
(FY 2022)
- Profit -48.94%
(FY 2022)
- Ebitda -194.61%
(FY 2022)
- Net Worth -22.43%
(FY 2022)
- Total Assets 5.33%
(FY 2022)
About Eos Pharmaceuticals India
The Corporate was formerly known as Acme Pharmaceuticals India Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹8.42 M.
Bhushan Nanda, Vishal Nanda, and Monika Nanda serve as directors at the Company.
- CIN/LLPIN
U24232DL2008PLC186122
- Company No.
186122
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Dec 2008
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Eos Pharmaceuticals India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishal Nanda  | Managing Director | 24-Dec-2008 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bhushan Nanda | Director | 24-Dec-2008 | Current |
| Monika Nanda | Director | 24-Dec-2008 | Current |
Financial Performance of Eos Pharmaceuticals India.
Eos Pharmaceuticals India Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 34.99% decrease. The company also saw a substantial fall in profitability, with a 48.94% decrease in profit. The company's net worth observed a substantial decline by a decrease of 22.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eos Pharmaceuticals India?
In 2021, Eos Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Jul 2020 | ₹0.92 M | Open |
Others Creation Date: 21 Jun 2017 | ₹3.50 M | Open |
Others Creation Date: 19 Jun 2017 | ₹1.50 M | Open |
How Many Employees Work at Eos Pharmaceuticals India?
Eos Pharmaceuticals India has a workforce of 6 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eos Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eos Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
